Novartis isn’t messing around with CAR-T, and it has a promising next-gen therapy to help prove it – Endpoints News
|
Novartis isn't messing around with CAR–T, and it has a promising next-gen therapy to help prove it
Endpoints News Novartis made one of the biggest splashes when it jumped into CAR–T — reengineering patients' immune cells to attack cancer cells — with Carl June and his colleagues at Penn. And the Big Pharma player stunned the oncology field last summer when it … |
